Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients
Abstract
Background High-grade gliomas are among the most aggressive central nervous system primary tumors, with a high risk of recurrence and a poor prognosis. Re-operation, re-irradiation, chemotherapy are options in this setting. No-best therapy has been established. Bevacizumab was approved on the basis of two Phase 2 trials that evaluated its efficacy in patients with recurrent glioblastoma. Materials and methods We have retrospectively review data...
Paper Details
Title
Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients
Published Date
Jun 3, 2021
Journal
Volume
126
Issue
9
Pages
1249 - 1254
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History